An interventional study of Domain Intervention(s) and Control / Standard of Care Comparator in Heart Failure, sponsored by University of Alberta. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University of Alberta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Heart Failure by University of Alberta — 11 open to participants now, 11 under way, none of them phase 3. Heart Failure · University of Alberta.
Among the 30 studies in Heart Failure by University of Alberta, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2027, is one of 13 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 26th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →11 of the 30 studies in Heart Failure by University of Alberta are open now, in 1 country. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 8–18
University of Alberta · Sites in Canada
Ages 60+ · Women only
University of Alberta · Sites in Canada
Ages 16+ · Healthy volunteers
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 2 · Phase 4 4
First in 2002; this study’s year is marked. 3 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 25 interventional studies, 200 across the 5 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
6 of the studies in Heart Failure by University of Alberta that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06595147University of AlbertaBreast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study | 2026-12-20 |
| NCT06969560University of AlbertaWeRoaM: Wearable Remote Monitoring in Heart Failure | 2026-12-31 |
| NCT05376254University of Alberta3D Assessment of RV Function in Patients Undergoing LVAD Implantation | 2027-01-19 |
| NCT06570473University of AlbertaFeasibility Trial for a Right Ventricular Failure Platform Trial | 2027-03-31 |
| NCT07434466University of AlbertaKetone Ester for Treatment Of Acute Heart Failure | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 30 studies in Heart Failure by University of Alberta, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.
The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform clinical trial infrastructure designed to improve outcomes for adults with heart failure through the efficient and continuous evaluation of multiple interventions. The platform enables the simultaneous and sequential testing of therapies across the spectrum of heart failure, with the ability to add, modify, or close interventions ("domains") over time as evidence accumulates and new research questions emerge.
HEART uses a master protocol framework with Domain-Specific Appendices (DSAs) that provide intervention-specific eligibility criteria, procedures, safety monitoring, and outcomes, while using shared platform-wide processes for governance, operations, data collection, and participant protections. This modular documentation structure allows platform updates and domain evolution without requiring complete revisions to all platform components, supporting long-term sustainability and reduced regulatory burden.
Participants are enrolled into one of two mutually exclusive patient states at the time of randomization: (1) State 1: Worsening Heart Failure (WHF), which includes patients hospitalized or treated in the emergency department for acute heart failure requiring active management; and (2) State 2: Ambulatory Heart Failure, which includes stable outpatients with established heart failure receiving ongoing management and without recent heart failure hospitalization. Patient state determines eligibility for specific domains and supports state-specific analyses.
Each HEART domain operates as a semi-autonomous trial within the broader infrastructure, with domain-specific scientific leadership and funding, while benefiting from shared core trial procedures. Domains may be conducted as vanguard/feasibility studies, Phase II trials, or Phase III trials, depending on the maturity of evidence and research objectives, and interventions may advance ("graduate") to later-phase evaluations within the platform.
The default primary endpoint for Phase III trials within the platform is time to first event of death or cardiovascular hospitalization; however, specific primary outcomes are determined at the domain level to match the intervention and development phase.
The HEART Platform incorporates formal governance and safety oversight, including a Platform Steering Committee and independent Data Safety Monitoring Board (DSMB), with standardized adverse event definitions and reporting procedures. The platform is conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and applicable ethical and regulatory requirements, with ethics approval obtained for the master protocol and each individual domain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (HEART Platform)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive one of the active intervention strategies being evaluated within eligible HEART Platform domains at the time of randomization. Eligible domains and interventions may change over time as domains are initiated, modified, or closed.
Other: Domain Intervention(s)
Participants will be randomized to a concurrent control group within eligible HEART Platform domains. The control group may include placebo and/or standard-of-care management, as specified in each active domain protocol.
Other: Control / Standard of Care Comparator
Participants randomized to the experimental arm will receive an intervention being evaluated within an eligible HEART Platform domain at the time of randomization. Domain interventions may change over time as domains are added, modified, or closed in accordance with the platform master protocol and domain-specific protocols.
Participants randomized to the comparator arm will receive concurrent control within eligible HEART Platform domains. Control may include placebo and/or standard-of-care management, depending on the domain-specific protocol.
Time to first occurrence of all-cause death or cardiovascular hospitalization
Time from randomization to the first event of all-cause death or cardiovascular hospitalization. This represents the platform default primary endpoint for Phase III domain evaluations. Outcomes for each intervention are defined within each HEART Platform domain protocol. The outcome measures listed in this registration represent platform-level outcomes and default endpoints used across domains where applicable.
Time frame: Up to 365 days (or as defined in domain-specific protocol)
All-cause mortality
All-cause mortality after randomization.
Time frame: Up to 365 days
Cardiovascular hospitalization
Occurrence of cardiovascular hospitalization after randomization.
Time frame: Up to 365 days
Heart failure hospitalization
Occurrence of hospitalization due to worsening heart failure.
Time frame: Up to 365 days
All-cause hospitalization
Occurrence of any hospitalization for any cause during the follow-up period of up to 365 days.
Time frame: Up to 365 days
Quality-adjusted days alive and out of the hospital
Number of days alive and out of hospital following randomization, adjusted for health-related quality of life.
Time frame: Up to 365 days
Organ-support free days
Number of days alive and free of organ support (e.g., mechanical ventilation, vasopressor therapy, or renal replacement therapy) within 30 days of enrollment.
Time frame: Up to 30 days
Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score
KCCQ Overall Summary Score, a patient-reported measure of heart failure symptoms, physical and social function, and quality of life. Scores range from 0 to 100, with higher scores indicating better health status. Assessed at follow-up time points up to 365 days.
Time frame: Up to 365 days
EQ-5D-5L Health Utility Score
Health-related quality of life measured using the EQ-5D-5L instrument. The EQ-5D-5L index score typically ranges from less than 0 (worse than death) to 1 (perfect health), with higher scores indicating better health status. Assessed at follow-up time points up to 365 days.
Time frame: Up to 365 days
No study locations are listed for this record.
Start is estimated for Jan 2027; primary completion for Mar 2036, 110 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 110 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.